Drugs / Ilorasertib
Ilorasertib
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT02540876 | Sep 2015 → Feb 2019 | metastatic malignant neoplasm | University of Chicago | Completed | No outcome recorded |
| Phase 1 | NCT01110473 | Apr 2010 → Jun 2013 | B-cell chronic lymphocytic leukemia, acute myeloid leukemia, chronic myeloid leukemia, myelodysplastic syndrome | AbbVie | Completed | No outcome recorded |
| Phase 1 | NCT01110486 | Mar 2010 → Sep 2013 | cancer | AbbVie | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT02478320 | Aug 2016 → May 2022 | high grade malignant neoplasm | M.D. Anderson Cancer Center | Terminated | No outcome recorded |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ilorasertib | “Ilorasertib (ABT-348) is a novel inhibitor of Aurora kinase, vascular endothelial growth factor (VEGF) and platelet-derived growth factor receptors, and the Src families of...” PMID 25933833 ↗ May 20153“Clinical pharmacodynamic/exposure characterisation of the multikinase inhibitor ilorasertib (ABT-348) in a phase 1 dose-escalation trial.” PMID 29551775 ↗ Mar 2018 |
| Known as | A-968660 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1980297 ↗ |
| Known as | A-968660.0 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1980297 ↗ |
| Known as | ABBOTT-968660 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1980297 ↗ |
| Known as | ABT-348 | “Clinical pharmacodynamic/exposure characterisation of the multikinase inhibitor ilorasertib (ABT-348) in a phase 1 dose-escalation trial.” PMID 29551775 ↗ Mar 2018 |
| Known as | Abt-348, a-968660 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1980297 ↗ |
| Action | Inhibit | “a novel inhibitor of Aurora kinase” PMID 25933833 ↗ May 2015 |
| Modality | Small molecule | — CHEMBL1980297 ↗ |
| Route | Oral | “An oral dose of ABT-348, once daily on Day 1, Day 8, and Day 15 of each 28 day cycle.” NCT01110473 ↗ |